Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Arizona
- Enrollment
- 67
- Locations
- 1
- Primary Endpoint
- Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1)
Study Overview
Brief Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in the immune system that may help kill cancer cells.
PURPOSE: This laboratory study is looking at anticancer immune responses in the peripheral blood of patients with colon cancer.
Detailed Description
OBJECTIVES:
- Quantify T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) from the peripheral blood of patients with colon cancer.
OUTLINE: This is an open-label study.
Patients undergo blood collection at time of follow-up, surgery, thoracentesis, paracentesis, or leukapheresis (≤ 5 times per year). Blood is analyzed for tumor peptides (carcinoembryonic antigen and MUC1), circulating cytokines, and lymphocyte response by ELISA, ELISPOT, or intracellular flow.
PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1)
Time Frame: 3 months
Secondary Outcomes
No secondary outcomes reported